Madison Investment Holdings Inc. grew its holdings in Bristol-Myers Squibb Co (NYSE:BMY) by 1,168.3% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 57,376 shares of the biopharmaceutical company’s stock after buying an additional 52,852 shares during the quarter. Madison Investment Holdings Inc.’s holdings in Bristol-Myers Squibb were worth $2,982,000 at the end of the most recent reporting period.
Other large investors have also made changes to their positions in the company. Portfolio Solutions LLC bought a new position in Bristol-Myers Squibb during the fourth quarter worth about $37,000. Gantzert Investment Co. LLC ADV bought a new position in Bristol-Myers Squibb during the fourth quarter worth about $39,000. 1 North Wealth Services LLC bought a new position in Bristol-Myers Squibb during the fourth quarter worth about $42,000. Larson Financial Group LLC bought a new position in Bristol-Myers Squibb during the fourth quarter worth about $64,000. Finally, Arlington Partners LLC boosted its holdings in Bristol-Myers Squibb by 40.0% during the fourth quarter. Arlington Partners LLC now owns 1,400 shares of the biopharmaceutical company’s stock worth $73,000 after buying an additional 400 shares during the last quarter. Institutional investors own 73.35% of the company’s stock.
BMY has been the topic of a number of recent analyst reports. BMO Capital Markets restated a “buy” rating and set a $60.00 target price on shares of Bristol-Myers Squibb in a report on Thursday, January 3rd. Societe Generale upgraded Bristol-Myers Squibb from a “sell” rating to a “buy” rating in a report on Tuesday, January 15th. Zacks Investment Research upgraded Bristol-Myers Squibb from a “hold” rating to a “buy” rating and set a $60.00 target price on the stock in a report on Tuesday, March 5th. Morgan Stanley set a $54.00 target price on Bristol-Myers Squibb and gave the stock a “hold” rating in a report on Thursday, December 20th. Finally, Credit Suisse Group restated a “hold” rating and set a $59.00 target price on shares of Bristol-Myers Squibb in a report on Thursday, December 13th. One analyst has rated the stock with a sell rating, eleven have assigned a hold rating and eight have given a buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus target price of $59.40.
NYSE BMY opened at $49.89 on Friday. The stock has a market cap of $82.25 billion, a PE ratio of 12.54, a price-to-earnings-growth ratio of 2.22 and a beta of 0.81. The company has a current ratio of 1.61, a quick ratio of 1.50 and a debt-to-equity ratio of 0.40. Bristol-Myers Squibb Co has a one year low of $44.30 and a one year high of $67.44.
Bristol-Myers Squibb (NYSE:BMY) last released its quarterly earnings results on Thursday, January 24th. The biopharmaceutical company reported $0.94 EPS for the quarter, topping the Zacks’ consensus estimate of $0.85 by $0.09. The company had revenue of $5.97 billion for the quarter, compared to analyst estimates of $5.95 billion. Bristol-Myers Squibb had a return on equity of 48.99% and a net margin of 21.95%. Bristol-Myers Squibb’s revenue was up 9.6% compared to the same quarter last year. During the same quarter last year, the firm posted $0.68 earnings per share. Research analysts anticipate that Bristol-Myers Squibb Co will post 4.15 earnings per share for the current fiscal year.
The firm also recently declared a quarterly dividend, which will be paid on Wednesday, May 1st. Stockholders of record on Friday, April 5th will be given a dividend of $0.41 per share. This represents a $1.64 dividend on an annualized basis and a dividend yield of 3.29%. The ex-dividend date is Thursday, April 4th. Bristol-Myers Squibb’s dividend payout ratio is currently 41.21%.
Bristol-Myers Squibb Company Profile
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers drugs in oncology, immunoscience, cardiovascular, and fibrotic diseases. The company's products include Opdivo, a biological product for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in adult patients with non-valvular atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders; and Orencia, a biological product for adult patients with moderately to severely active RA and prostate-specific antigen, as well as reducing signs and symptoms in certain pediatric patients with moderately to severely active polyarticular juvenile idiopathic arthritis.
Featured Article: Lock-Up Period Expiration
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.